Federico Cappuzzo

Director and Chief of Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute Personal Statement My interest in the field of medical oncology dates back to the early nineties. In those years, following my graduation in Medicine and Surgery at the University of Palermo, I focused on a postdoctoral fellowship in medical oncology, which I accomplished in 1996 at the University of Milan. Since then, I’ve been strongly committed to gain methodological skills in clinical and translational research and to manage cancer patients in full agreement with the most updated national and international guidelines and according to their individual needs. To these purposes, I further trained as a postdoctoral fellow in Medical Oncology at the National Cancer Institute in Milan. Subsequently, I was awarded with a fellowship on gene therapy of lung cancer at the Institut Gustave Roussy in Villejuif (Paris). Then, I strengthened my experience in clinical practice and applied the fundamental tenets of cancer research at the Bellaria Hospital in Bologna. I subsequently joined a further postdoctoral program in thoracic oncology at medical University of South Carolina in Charleston (USA). I was then appointed Assistant Professor in Medical Oncology at Istituto Clinico Humanitas IRCCS in Rozzano (Milano), with a special focus in translational research in lung and colorectal cancer. I pursued these same interests while acting as Director of Medical Oncology at the Ospedale Civile in Livorno, wherein I was also appointed Director of the Oncology Department. In Ravenna, I was then appointed Director of Medical Oncology at the Santa Maria delle Croci Hospital in Ravenna. Through the following years, I covered similar tasks while acting as Director of the Department of Oncology and Hematology at the AUSL Romagna. In 2017, I was appointed Full Professor in medical Oncology at the National Level. I then joined the colleagues of the IRCCS Regina Elena Cancer Institute, where I’ve been recently appointed Director of the Division of Medical Oncology 2. Within such a context, my strongest commitments relate to perform clinical and translation research, develop and participate in clinical trials at a national and international level. I’m further committed to take a leadership role in clinical operation, education, and research within the Division of Medical Oncology 2 and to implement and expand these same activities in the frame of multidisciplinary collaborations at the departmental level. Active and scientifically sound collaborations with other national and international Institutions striving for excellence in cancer research and care will also include exchange programs for PhD students and postdoctoral fellows in the field of Medical Oncology. Positions, Scientific Appointments, and Honors - Since January 1994, Member of Italian Association in Medical Oncology (AIOM). - Since March 1996, Member of European Society for Medical Oncology (ESMO). - Since April 2001, Member of American Society Clinical Oncology (ASCO). - Since June 2004, Member of International Association for the Study of Lung Cancer (IASCL). - Since 2006 Member of the editorial board of Lung Cancer - Since January 1997, General Medical Council (GMC) Registration. - From 2013 to 2017, chair of the educational committee of the International Association for the Study of Lung Cancer (IASLC) - From May 2014 to July 2016, President of the Translational Research Foundation (FoRT) Patents: - 17 April 2008: United States Patent Application Publication (US 2008/0090233) on “Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients”. - 2010: United States Patent Application for MYC detection as predictor for sensitivity to anti-EGFR therapies in non-small-cell lung cancer Contributions to Science Research founding: - 2006-2008: Research Grant from the Italian Association for Cancer Research (AIRC) on targeted therapies in cancer. - 2009-2011: Research grant from the Italian Association for Cancer Research (AIRC) on mechanisms of resistance to targeted therapies in lung and colorectal cancer. - 2012-2014: Research grant from the Italian Association for Cancer Research (AIRC): Cancer Stem Cells Sensitivity Assay for Metastatic Non-Small-Cell Lung Cancer patients. - 2012-2013: Research grant from the Istituto Toscano Tumori on MIR128 and LET7 expression and efficacy of anti-EGFR therapies in metastatic NSCLC with EGFR or KRAS mutations. - 2014: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study “Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS)”. - 2016: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study “SQUINT (Squamous Immunotherapy Nivolumab Trial): An open-label, randomized, phase II trial of nivolumab-ipilimumabversus platinum-based chemotherapy in chemonaive metastatic or recurrent Squamous-Cell Lung Cancer (SqLC)”. - 2016: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study “PF-06463922 for crizotinib pretreated ROS1 positive nonsmall-cell lung cancer: a phase II Trial (PFROST)”. - 2017: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study “Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation (CABinMET) - 2017: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study “SpeciALK: Crizotinib in ALK rearranged non-small-cell lung cancer: a retrospective study in patients treated in the Italian named patient use program” - 2017: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study ““FLIBER: Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC)” - 2018: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study “Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1+ advanced metastatic non-small-cell lung cancer patients (BEAT trial)” - 2018: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study “STARDUST: Phase II trial evaluating the efficacy of durvalumab as second-line therapy in Non-Small-Cell Lung Cancer patients receiving concomitant steroids” - 2019: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study CAPLAND: “A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations” - 2019: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study NTRK: “NTRK 1,2,3 rearrangements in patients with solid tumors” - 2019: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study BRICE: “A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer and Expansion Phase in Subjects with Advanced EGFR mutated Non-Small Cell Lung Cancer who are resistant to EGFR tyrosine kinase inhibitors” - 2019: Research grant from Fondazione Ricerca Traslazionale (FoRT) for the study” A phase II, two cohorts, randomized trial comparing standard of care versus immune-based combination in relapsed stage III non- small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab”.